FDA offers solution for generic approvals during label changes; AbbVie to buy back shares;

@FiercePharma: Shire's Vyvanse tops $1B as more generics challenge Adderall. Report | Follow @FiercePharma

@EricPFierce: Mylan currently the focus of a hot rumor for picking up the sterile injectables unit of India's Strides Arcolab. News | Follow @EricPFierce

@AlisonBFierce: A promising new vaccine--administered as a nasal spray--is shrinking head and neck tumors. More | Follow @AlisonBFierce

> The FDA has come out with a plan for approving generic drugs even when the drug they are copying is in the midst of a label change. Story

> New spin-off AbbVie ($ABBV) says it will buy back $1.5 billion in shares over the next couple of years. News

> A federal court has upheld two patents held by Cephalon, which is now owned by Teva ($TEVA), related to the cancer drug Fentora, turning back a generic challenge by Actavis ($ACT). Report

> After years of appeals, Sanofi ($SNY) has won a tax case in India that tried to nail it for capital gains taxes when it acquired Shantha in 2009. Article

Medical Device News

 @FierceMedDev: Cohera snags $17M to support TissuGlu. News | Follow @FierceMedDev

 @MarkHFierce: Weight loss devices never go out of style. BAROnova secured a $27.3M Series C for its contribution to the space. More | Follow @MarkHFierce

 @DamianFierce: St. Jude is studying whether renal denervation can treat heart attack and stroke in addition to hypertension. Press release | Follow @DamianFierce

> Acquisitions help boost Alere's 2012 Q4 revenue. Item

> J&J braces international market for more metal hip problems. Article

> Second Sight scores victory with FDA nod for retinal prosthesis. News

Biotech News

 @FierceBiotech: Still trending: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Mega-mergers are back (expect 1-2 big deals in biopharma this year). News | Follow @JohnCFierce

@RyanMFierce: Japan takes lead in trialing a human stem cell therapy. Story | Follow @RyanMFierce

> GSK's Slaoui talks up 'innovative' late-stage pipeline as regulatory reviews loom. Article

> Biotech benefits from 'breakthrough' guess for its cancer med partnered with J&J. News

> Blog: AbbVie slams brakes on cancer drug trials after patient death. Report

And Finally... After several years of quiet among prescription sleep aids, Purdue Pharma has issued a wake up call to the category with an ad campaign featuring an adorably memorable anthropomorphic lightbulb. Item

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.